Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at insiderspress.com, will continue to monitor these healthtech companies to see if the momentum continues. Insiders Press.
Recent LLY Stock Price: $757.64
Summary: Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Robyn Karnauskas analyst at Truist Financial reiterates coverage on Eli Lilly and Company (LLY) stock in the energy sector with a Buy rating and has set LLY's stock price target at $771.92.
TipRanks.com reports that Eli Lilly and Company currently has 5 analysts offering 12-month price targets on LLY and the consensus is a Buy rating with an average stock price target of $828.38. The most recent LLY stock price we have is $757.64 and we are not making any LLY forecasts at this time.
In addition, TradingView issued a buy rating for LLY over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LLY. insiderspress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on LLY, please click here >>
Regeneron Pharmaceuticals, Inc., REGN
Recent REGN Stock Price: $987.61
Summary: Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
Brian Abrahams analyst at RBC Capital reiterates coverage on Regeneron Pharmaceuticals, Inc. (REGN) stock in the energy sector with a Buy rating and has set REGN's stock price target at $1184.
TipRanks.com reports that Regeneron Pharmaceuticals, Inc. currently has 5 analysts offering 12-month price targets on REGN and the consensus is a Buy rating with an average stock price target of $1,071.44. The most recent REGN stock price we have is $987.61 and we are not making any REGN forecasts at this time.
In addition, TradingView issued a buy rating for REGN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on REGN. insiderspress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on REGN, please click here >>
Biogen Inc., BIIB
Recent BIIB Stock Price: $221.74
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Brian Abrahams analyst at RBC Capital reiterates coverage on Biogen Inc. (BIIB) stock in the energy sector with a Buy rating and has set BIIB's stock price target at $364.
TipRanks.com reports that Biogen Inc. currently has 5 analysts offering 12-month price targets on BIIB and the consensus is a Buy rating with an average stock price target of $301.40. The most recent BIIB stock price we have is $221.74 and we are not making any BIIB forecasts at this time.
In addition, TradingView issued a sell rating for BIIB over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on BIIB. insiderspress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BIIB, please click here >>
The editors at insiderspress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
Insiders Press
==============================================================================
